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Abstract. 
 
We previously demonstrated that bone mor-
phogenetic proteins (BMPs) induce cardiomyocyte differ-
 
entiation through the mitogen-activated protein kinase
kinase kinase TAK1. Transcription factors Smads medi-
 
ate transforming growth factor-
 
b
 
 signaling and the
ATF/CREB family transcription factor ATF-2 has re-
cently been shown to act as a common target of the
Smad and the TAK1 pathways. We here examined the
role of Smads and ATF-2 in cardiomyocyte differen-
tiation of P19CL6, a clonal derivative of murine P19
cells. Although P19CL6 efﬁciently differentiates into
cardiomyocytes when treated with dimethyl sulfoxide,
P19CL6noggin, a P19CL6 cell line constitutively over-
expressing the BMP antagonist noggin, did not dif-
ferentiate into cardiomyocytes. Cooverexpression of
Smad1, a ligand-speciﬁc Smad, and Smad4, a common
Smad, restored the ability of P19CL6noggin to differen-
tiate into cardiomyocytes, whereas stable overexpres-
sion of Smad6, an inhibitory Smad, completely blocked
differentiation of P19CL6, suggesting that the Smad
pathway is necessary for cardiomyocyte differentiation.
 
ATF-2 stimulated the 
 
b
 
MHC promoter activity by
the synergistic manner with Smad1/4 and TAK1 and
 
promoted terminal cardiomyocyte differentiation of
P19CL6noggin, whereas overexpression of the dominant
negative form of ATF-2 reduced the promoter activities
of several cardiac-speciﬁc genes and inhibited differenti-
ation of P19CL6. These results suggest that Smads,
TAK1, and their common target ATF-2 cooperatively
play a critical role in cardiomyocyte differentiation.
Key words: bone morphogenetic protein • Smad •
ATF-2 • cardiomyocyte differentiation • P19CL6
 
Introduction
 
The heart forms through multiple developmental steps such
as determination of the cardiac field in the mesoderm, differ-
entiation of cardiac precursor cells into cardiomyocytes, and
morphogenesis of the chambered heart (Nascone and Mer-
cola, 1995; Olson and Srivastava, 1996). Many classical em-
bryonic studies have implicated the mechanisms of how and
where these steps take place in the developing embryos. The
 
vertebrate heart arises from paired mesodermal primordia
that migrate to the anterior ventral midline, where they fuse
and undergo terminal differentiation (Rosenquist and De-
 
haan, 1966; Han et al., 1992). In 
 
Xenopus
 
 embryos, the car-
diac field is located in the dorsal mesoderm lateral to the
Spemann organizer and is specified before the end of gas-
trulation. In this relatively early step of cardiac develop-
ment, inductive signals from the adjacent deep endoderm
and the organizer region have been shown to play an impor-
tant role in determination of the cardiac field. It has been re-
ported that the presence of deep dorsoanterior endoderm
markedly enhances the heart formation in explants of heart
primordia and that the presence of both the endoderm and
the organizer is necessary and sufficient to induce beating
heart tissue in ventral mesoderm explants (Nascone and
Mercola, 1995). In chicks, the anterior endoderm also has
been shown to induce differentiation of nonprecardiac meso-
dermal cells into heart tissue (Schultheiss et al., 1995). These
observations suggest that the endoderm-derived signals play
a vital role both in specification of the cardiac field and in dif-
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ferentiation of determined cardiac precursor cells. However,
little is known about the molecular mechanisms that regulate
these inductive events during the formation of the heart.
Recently, 
 
decapentaplegic
 
 (
 
dpp
 
) and bone morphoge-
netic proteins (BMPs),
 
1
 
 which are the members of the
TGF-
 
b 
 
superfamily, have been demonstrated to be impor-
tant candidates that regulate expression of some cardiac-
enriched transcription factors such as 
 
tinman
 
, Csx/Nkx-2.5,
and GATA-4 and induce cardiomyocyte differentiation.
In 
 
Drosophila
 
, it has been reported that expression of 
 
tin-
man
 
 is restricted to the dorsal part of the mesoderm by the
ectodermally expressed 
 
dpp
 
, which is most closely related
to vertebrate BMP-2 or BMP-4 (Frasch, 1995). Subse-
quently, experiments using chick embryos have demon-
strated that expression of BMP-2/BMP-4 is detected in the
ectoderm or the endoderm adjacent to the precardiac me-
soderm and that ectopic expression of BMP-2 induces dif-
ferentiation of nonprecardiac mesodermal cells into beat-
ing cardiomyocytes (Schultheiss et al., 1997), suggesting that
BMPs play a pivotal role in induction of vertebrate cardiac
development. Furthermore, gene targeting experiments
have shown that normal cardiac development is impaired
both in BMP-2 and BMP-4 knockout mice (Winnier et al.,
1995; Zhang and Bradley, 1996). These results indicate that
BMPs are required for normal cardiac development.
However, the precise molecular mechanisms by which
BMPs regulate cardiogenesis have been largely unknown
because of the complexity in the in vivo situation. From this
viewpoint, we used P19CL6, an in vitro system of cardio-
myocyte differentiation to dissect the cardiogenic pathways
mediated by BMPs. P19CL6 is a clonal derivative isolated
from murine P19 embryonic carcinoma cells by limiting di-
lution method (Habara-Ohkubo, 1996). Unlike P19 cells,
whose utility is limited because of their multipotential prop-
erties, this CL6 subline efficiently differentiates into beating
cardiomyocytes with adherent conditions when treated with
1% DMSO. As almost all cells differentiate into cardio-
myocytes with expression of cardiac-specific genes, P19CL6
is thought to be a useful in vitro model to study cardiomyo-
cyte differentiation (Habara-Ohkubo, 1996).
By using the P19CL6 in vitro system, we previously
demonstrated that BMPs are indispensable for cardiomyo-
cyte differentiation and that BMPs induce cardiomyocyte
differentiation through TAK1, a member of the mitogen-
activated protein kinase kinase kinase (MAPKKK) family
that has been demonstrated to be involved in TGF-
 
b
 
 sig-
naling (Monzen et al., 1999). As well as TAK1, the Smad
proteins have been identified and characterized as impor-
tant mediators of TGF-
 
b
 
 signal transduction pathways
(Heldin et al., 1997; Attisano and Wrana, 1998; Massagué,
1998). Among the members of Smads, Smad1, Smad5, and
Smad8 transduce signals from BMPs specifically, whereas
Smad4 is a general partner of ligand-specific Smads. After
ligand stimulation and phosphorylation of ligand-specific
Smads by the receptors, Smad4 forms heterooligomers
with ligand-specific Smads, which in turn translocate into
the nucleus and activate transcriptional responses. Recent
 
studies in 
 
Drosophila
 
 have shown that Dpp-induced 
 
tin-
man
 
 gene expression is positively regulated by the Smad4
homologue Medea (Xu et al., 1998), suggesting that the
Smads-mediated signal transduction pathway is also in-
volved in the BMP-induced differentiation into cardio-
myocytes. Therefore, we investigated the role of Smads in
cardiomyocyte differentiation of P19CL6 in this study.
ATF-2 is a member of the ATF/CREB family transcrip-
tion factors, all of which contain a DNA binding domain,
b-ZIP, consisting of a cluster of basic amino acids and leu-
cine zipper structures (Maekawa et al., 1989; Busch and
Sassone-Corsi, 1990). They form dimers through their leu-
cine zipper regions and bind to cAMP response element
(CRE). ATF-2 is phosphorylated and stimulated by stress-
activated protein kinases (SAPKs) such as c-Jun NH
 
2
 
-ter-
minal kinases (JNKs) and p38 at Thr-69, Thr-71, and Ser-90
which lie close to the NH
 
2
 
-terminal transcriptional activa-
tion domain (Gupta et al., 1995) and binds to CRE with
high affinity as a homodimer or a heterodimer with c-Jun
(Macgregor et al., 1990; Hai and Curran, 1991). Recently,
ATF-2 has been reported to bind directly to heterooligo-
mers of Smads and be phosphorylated by TGF-
 
b
 
 signaling
via TAK1 and p38, indicating that ATF-2 is a common nu-
clear target of the Smad and the TAK1 pathways in TGF-
 
b
 
signaling (Hanafusa et al., 1999; Sano et al., 1999). The ac-
tions caused by both pathways are shown to be responsible
for the synergistic stimulation of ATF-2 transactivating ca-
pacity (Sano et al., 1999). From this point of view, we have
examined the involvement of ATF-2 in BMP-induced car-
diomyocyte differentiation in this study.
Here we demonstrate several lines of evidence which
suggest that Smads, TAK1, and their common down-
stream target ATF-2 cooperatively play a critical role in
differentiation of P19CL6 cells into cardiomyocytes.
 
Materials and Methods
 
Plasmids
 
Expression plasmids constructed by inserting FLAG-tagged murine
Smad1, Smad4, and Smad6 into pcDNA3 vectors were described previ-
ously (Imamura et al., 1997). Expression plasmids encoding the TAK1
mutants (Yamaguchi et al., 1995), murine GATA-4 (Arceri et al., 1993),
and murine MEF2C cDNA (Lin et al., 1997) were provided by H. Shibuya
(Okazaki, Japan), D.B. Wilson (St. Louis, MO), and E.N. Olson (Dallas,
TX), respectively. Expression plasmids containing human wild-type ATF-2
cDNA and the ATF-2 mutants (ATF-2Ala and ATF-2
 
D
 
107) were de-
scribed previously (Matsuda et al., 1991; Sano et al., 1999). Plasmids con-
taining luciferase gene driven by 
 
b
 
MHC, atrial natriuretic peptide (ANP),
brain natriuretic peptide (BNP), and skeletal 
 
a
 
-actin promoters were also
described previously (Takano et al., 1998; Shiojima et al., 1999). Expres-
sion plasmids encoding green fluorescent protein (GFP) was commer-
cially purchased (pEGFP-1; CLONTECH Laboratories, Inc.).
 
Cell Culture and Differentiation
 
P19CL6 cells were cultured essentially as described previously (Habara-
Ohkubo, 1996). In brief, the cells were grown in a 100-mm tissue culture
grade dish under adherent conditions with 
 
a
 
-minimal essential medium
(GIBCO BRL), supplemented with 10% FBS (JRH Bioscience), penicil-
lin (100 U/ml), and streptomycin (100 
 
m
 
g/ml) (growth medium), and were
maintained in a 5% CO
 
2
 
 atmosphere at 37
 
8
 
C. To induce differentiation
under adherent conditions, P19CL6 cells were plated at a density of 3.7 
 
3
 
10
 
5
 
 cells in a 60-mm tissue culture grade dish with the growth medium con-
taining 1% DMSO (differentiation medium). The medium was changed
every 2 d. Days of differentiation were numbered consecutively after the
first day of DMSO treatment as day 0. Natural bovine BMP cocktail
 
1
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(Sangi) which contains almost all types of bone-derived BMPs including
BMP-2 and BMP-4 was added into the differentiation medium at a final
concentration of 100 ng/ml.
 
Stable Transformants
 
Establishment of P19CL6noggin was described previously (Monzen et al.,
1999). To isolate the permanent cell line P19CL6Smad6, P19CL6 cells were
transfected with pcDNA3-Smad6 (Imamura et al.
 
,
 
 1997) by the lipofection
method (Tfx™ Reagents; Promega). Stable transformants were selected with
400 
 
m
 
g/ml of neomycin (G418), and six independent cell lines were cloned.
 
Transfection and Reporter Assay
 
To examine the differentiation ability of P19CL6 and P19CL6noggin cells,
the cells were transfected with expression vectors containing Smad1,
Smad4, Smad6, the TAK1 mutants, and the ATF-2 mutants on day 3 of
differentiation according to the lipofection method as recommended
(Promega). The morphological features and the beating ability of the cells
were observed accompanied by immunostaining with MF20 on day 12 or
day 14 as described below. To test the promoter activities, the cells were
transfected simultaneously with effector and reporter plasmids on day 5
by the calcium phosphate method and then the cell lysates were extracted
on day 7. The luciferase activities were measured as described previously
(Takano et al., 1998).
 
Immunofluorescence
 
Immunostaining with MF20, a monoclonal antibody against sarcomeric
MHC, was performed as described previously (Bader et al., 1982) using
anti–mouse immunoglobulin G conjugated with tetramethyl rhodamine
isothiocyanate as the secondary antibody. MF20-positive areas were mea-
sured on day 14 by directly tracing the stained areas on a photograph. Im-
munostaining with anti-FLAG antibody was performed as described pre-
viously (Zhu et al., 1999) using fluorescein isothiocyanate–conjugated
goat anti–mouse immunoglobulin G as the secondary antibody.
 
RNA Analysis
 
Total RNA was extracted by the acid guanidine method (RNAzol B™;
Biotecx Laboratories, Inc.), and Northern blot analysis was performed as
described previously (Monzen et al., 1999) with 10 
 
m
 
g of total RNA from
each sample for Smad6, GATA-4, MEF2C, MHC, MLC2v, and ATF-2.
The following cDNA fragments were used as probes: the EcoRI fragment
of pcDNA3 containing murine Smad6 cDNA (Imamura et al., 1997), the
EcoRI fragment of pMT2 containing murine GATA-4 cDNA (Arceri et
al., 1993), the EcoRI fragment of pcDNA1 containing murine MEF2C
cDNA (Lin et al., 1997), the PstI fragment of pMHC25 containing rat
skeletal muscle MHC cDNA (Takano et al., 1998), the EcoRI fragment of
pCRII containing PCR product obtained by using oligonucleotide primers
specific for MLC2v (Lyons et al., 1995), and the XbaI/HincII fragment of
pact-ATF-2 containing human ATF-2 cDNA (Sano et al., 1999). For the
analysis of Csx/Nkx-2.5 mRNA, reverse transcription (RT)-PCR was per-
formed as described previously (Monzen et al., 1999).
 
Detection of Phosphorylated ATF-2 Protein
 
To examine the phosphorylation of endogenous ATF-2, whole cell ex-
tracts from the P19CL6 cells on day 0 and day 6 of differentiation were
prepared as described previously (Shiojima et al., 1999). The cell extracts
were analyzed by SDS-PAGE followed by Western blotting. The phos-
phorylation of ATF-2 was examined using Phosphoplus ATF-2 (New En-
gland Biolabs, Inc.), which detects phosphorylation of Thr-71 specifically.
The protocols of SDS-PAGE and Western blot analysis were described
previously (Zhu et al., 1999).
 
Results
 
Cooverexpression of Smad1 and Smad4 Restored the 
Ability of P19CL6noggin Cells to Differentiate
into Cardiomyocytes
 
To elucidate the precise molecular mechanisms by which
BMP signaling regulates cardiomyocyte differentiation,
 
we used the P19CL6 in vitro system. When cultured in
growth medium without DMSO, P19CL6 cells grew well
and did not differentiate into any specific cells including
cardiomyocytes (Fig. 1 A, a and b). When 1% DMSO was
added to the medium, P19CL6 efficiently differentiated
into mononucleated, spontaneously contracting cardio-
myocytes, immunostained by antisarcomeric MHC anti-
body MF20 (Fig. 1 A, c and d). As described previously
(Habara-Ohkubo, 1996; Monzen et al., 1999), spontaneous
beating was first observed on a limited area on day 10
(10 d after the initiation of DMSO treatment), and subse-
quently, the majority of cells started to beat synchro-
nously. To test the requirement of BMPs for cardio-
myocyte differentiation, we previously established the
permanent cell line named P19CL6noggin, which constitu-
tively overexpresses the BMP antagonist noggin (Mon-
zen et al., 1999). In contrast to parental P19CL6 cells,
P19CL6noggin cells did not differentiate into cardiomyo-
cytes even when they were treated with 1% DMSO (Fig. 1
A, g), suggesting that BMPs are indispensable for car-
diomyocyte differentiation. To elucidate whether Smads
may mediate BMP-induced cardiomyocyte differentiation
of P19CL6, P19CL6noggin cells were transfected with ex-
pression plasmids containing Smad1 or Smad4 on day 3 by
the lipofection method and the differentiation ability was
assessed around day 14. Smad1 is one of ligand-specific
Smads and transduces signals from BMPs specifically,
whereas Smad4 is a general partner of ligand-specific
Smads. Unlike the control P19CL6noggin cells, the cells
transfected simultaneously with Smad1 and Smad4 par-
tially differentiated into beating cardiomyocytes positive
for MF20 by the treatment with DMSO (Fig. 1 A, j). On
the other hand, the cells transfected with Smad1 alone or
Smad4 alone did not differentiate into cardiomyocytes
(Fig. 1 A, h and i). The same results were obtained with at
least three independent cell lines.
Translocation of Smads into the nucleus and subsequent
transcriptional activation have been reported to require
heterooligomer formation of ligand-specific Smads and the
common mediator Smad4 after ligand stimulation and
phosphorylation of ligand-specific Smads by the receptors
(Lagna et al., 1996; Macias-Silva et al., 1996). To clarify
whether overexpression of exogenous Smad1 and Smad4
causes nuclear accumulation of the Smad proteins, we
examined the localization of exogenous FLAG-tagged
Smad1 in P19CL6noggin cells using anti-FLAG antibody.
P19CL6noggin cells were transfected with both expression
plasmids carrying FLAG-tagged Smad1 and those contain-
ing Smad4, and immunostained by anti-FLAG antibody
12 h later. In the absence of BMP stimulation, the staining
was highly positive in the cytosol, and less but surely posi-
tive in the nucleus (Fig. 1 B, a–d). On the other hand,
FLAG signals were detected predominantly in the nucleus
after BMP stimulation (Fig. 1 B, e and f). These observa-
tions suggest that a part of overexpressed Smads can move
into the nucleus even in the absence of BMP stimulation
and that the sufficient ligand stimulation accelerates the
translocation of exogenous Smads into the nucleus.
To characterize the correlation between overexpression
of Smads and the P19CL6 differentiation into cardiomyo-
cytes at the cellular level, we examined whether the differ-
entiation is surely induced in the cells overexpressing ex- 
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Figure 1.
 
Simultaneous overexpression of Smad1 and Smad4 restored the ability of P19CL6noggin cells to differentiate into cardio-
myocytes. (A) P19CL6 cells (a–d) and P19CL6noggin cells (e–j) were cultured in growth medium (a, b, e, and f) or in differentiation
medium containing 1% DMSO (c, d, g–j). Both parental P19CL6 cells (a and b) and P19CL6noggin cells (e and f) grew well and re-
mained undifferentiated in growth medium. Parental P19CL6 cells differentiated into beating cardiomyocytes when cultured in the me-
dium containing 1% DMSO. On day 14, most P19CL6 cells had differentiated into mononucleated contracting cardiomyocytes (c and
d). On the other hand, P19CL6noggin cells did not differentiate into beating cardiomyocytes even after treatment with DMSO (g). The
P19CL6noggin cells transfected with Smad1 alone (h) or Smad4 alone (i) did not differentiate into cardiomyocytes, whereas cooverex-
pression of Smad1 and Smad4 induced differentiation of P19CL6noggin cells into cardiomyocytes in the presence of DMSO (j). The
cells were stained with antisarcomeric myosin heavy chain antibody (MF20) (a, c–e, g–j) or Hoechst dye (b and f). Bars, 250 
 
m
 
m (d) and
50 
 
m
 
m (others). (B) The localization of exogenous Smad1 in P19CL6noggin cells. In the presence or the absence of BMP (100 ng/ml),
P19CL6noggin cells were transfected with expression vectors containing FLAG-tagged Smad1 and those containing Smad4, and immu-
nostained by anti-FLAG antibody 12 h later. (a, c, and e) Hoechst dye; (b, d, and f) immunostaining with anti-FLAG antibody. Arrows, 
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ogenous Smads. P19CL6noggin cells were transfected
simultaneously with expression vectors carrying Smad1/4
and those containing GFP on day 3 and then were stained
by MF20 on day 12. The immunostaining by MF20 were
detected in GFP-positive cells (Fig. 1 C, arrows) but not in
GFP-negative cells (Fig. 1 C, arrowheads), suggesting that
the myocyte differentiation was induced in the cells over-
expressing exogenous Smads but not in the cells which
were not transfected with Smads.
In parental P19CL6 cells, expression of cardiac tran-
scription factors such as Csx/Nkx-2.5, GATA-4, and
MEF2C was detected from day 6 and expression of con-
tractile protein genes such as MHC and MLC2v was ob-
served on day 12 (Fig. 1 D, lane 5; Fig. 2 B, lanes 1–3). Ex-
pression of these genes was induced also in P19CL6noggin
cells transfected simultaneously with Smad1 and Smad4,
but not in the control P19CL6noggin cells or the cells
transfected with Smad1 or Smad4 alone (Fig. 1 D, lanes 1–4).
These results indicate that cooverexpression of Smad1 and
Smad4 restored the ability of P19CL6noggin cells to dif-
ferentiate into cardiomyocytes with concomitant expres-
sion of some set of cardiac-specific genes, suggesting that
Smads may mediate the BMP-induced cardiomyocyte dif-
ferentiation.
We further examined whether ligand stimulation en-
hances the differentiation efficiency of P19CL6noggin
cells transfected with Smad1 and Smad4. The cells were
cultured with or without addition of the BMP protein to
the culture media at the concentration of 100 ng/ml from
day 0. The cells were transfected with Smad1 and Smad4
on day 3 by the lipofection method. To estimate the differ-
entiation efficiency, the percentage of areas positive for
MF20 were measured on day 14. When the BMP protein
was added to the media, some P19CL6noggin cells differ-
 
entiated into cardiomyocytes as we observed previously
(Monzen et al., 1999), implying that a sufficient amount of
BMP protein restored the ability of P19CL6noggin cells to
differentiate into cardiomyocytes. P19CL6noggin cells
transfected with Smad1 and Smad4 more efficiently differ-
entiated into cardiomyocytes stained by MF20 in the pres-
ence of the sufficient ligand stimulation compared with the
transfected cells in the absence of BMP (Fig. 1 E). The
percentage of positive areas was increased from 
 
z
 
25 to
60% by the addition of BMP in the Smad1/4-transfected
P19CL6noggin cells and from 
 
z
 
49 to 60% by overexpres-
sion of Smads in the presence of BMP stimulation, al-
though the latter increase was not significant (Fig. 1 F).
These results suggest that excessive ligand stimulation
overcomes the antagonistic effect of noggin and enhances
the differentiation efficiency through the Smad pathway
and further confirm the notion that Smads are involved in
BMP-mediated cardiomyocyte differentiation.
 
Overexpression of Smad6, an Inhibitory Smad, Blocked 
Cardiomyocyte Differentiation of P19CL6 Cells
 
Smad6 has been identified and characterized as an inhibi-
tory Smad, which forms stable association with BMP type
I receptors and interferes with the phosphorylation of
Smad1 (Imamura et al., 1997). Subsequent studies have re-
vealed that Smad6 also competes with Smad4 for binding
to Smad1 to block BMP signaling (Hata et al., 1998). To
elucidate the requirement of the Smad pathway for car-
diomyocyte differentiation, we isolated P19CL6 clones
which permanently overexpress murine Smad6 under the
control of human cytomegalovirus enhancer and desig-
nated them P19CL6Smad6. Northern blot analysis re-
vealed that abundant expression of exogenous Smad6
mRNA was observed throughout differentiation in
P19CL6Smad6 cells (Fig. 2 B, lanes 4–6). In contrast to pa-
rental P19CL6 cells, P19CL6Smad6 cells did not differen-
tiate into MF20-positive beating cardiomyocytes by the
treatment with DMSO (Fig. 2 A). The same results were
obtained with at least four independent P19CL6Smad6
cell lines.
Furthermore, RT-PCR and Northern blot analyses
revealed that, unlike parental P19CL6 cells, neither ex-
pression of cardiac transcription factors such as Csx/Nkx-
2.5, GATA-4, and MEF2C nor that of contractile pro-
tein genes such as MHC and MLC2v was detected in
P19CL6Smad6 cells during the course of the observation
(Fig. 2 B). These results suggest that the Smad pathway is
essential for expression of cardiac-specific genes and dif-
ferentiation of P19CL6 cells into cardiomyocytes.
 
The Expression Levels and the Activity of ATF-2 Were 
Increased during the Course of Differentiation of 
P19CL6 Cells
 
Although we have clarified that both the Smad pathway
and the TAK1 pathway play an important role in BMP-
induced cardiomyocyte differentiation in this study and the
previous study (Monzen et al., 1999), the relation between
both pathways has been largely unknown. Recently, how-
ever, the transcription factor ATF-2 has been reported to
be a common nuclear target of the Smad and the TAK1
pathways and play a central role in TGF-
 
b
 
 signaling (Sano
 
a FLAG-positive cell; arrowheads, a FLAG-negative cell. Bar, 20
 
m
 
m. (C) The correlation between overexpression of Smad1/4 and
the P19CL6 differentiation. P19CL6noggin cells were transfected
with expression plasmids encoding Smad1 and Smad4 along with
GFP expression plasmids on day 3 and then immunostained by
MF20 on day 12. (a) Hoechst dye; (b) GFP; (c) MF20. Arrows, a
GFP-positive cell; arrowheads, a GFP-negative cell. Bar, 20 
 
m
 
m.
(D) Expression of cardiac-specific genes in P19CL6noggin cells
overexpressing Smad1 and/or Smad4. RNA was extracted from
parental P19CL6 cells and P19CL6noggin cells transfected with
Smad1 and/or Smad4 on day 14. RT-PCR was performed for the
analysis of Csx/Nkx-2.5 mRNA. 10 
 
m
 
g of RNA from each sample
was subjected to Northern blot analysis for other genes. Ethid-
ium bromide staining of rRNA is presented at the bottom to
show that the same amount of intact RNA was loaded in each
lane. (E and F) Ligand stimulation enhanced the differentiation
efficiency of P19CL6noggin cells transfected with Smad1/4. (E)
Immunostaining with MF20. P19CL6noggin cells were cultured
with (c and d) or without BMP (a and b) in the culture media at
the concentration of 100 ng/ml from day 0. The cells were trans-
fected with Smad1/4 on day 3 by the lipofection method (b and
d). The cells were then immunostained with MF20 on day 14. By
the treatment with BMP, P19CL6noggin cells transfected with
Smad1/4 more efficiently differentiated into MF20-positive car-
diomyocytes. Bar, 250 
 
m
 
m. (F) Quantification of the areas
stained by MF20 in P19CL6noggin cells. The areas of at least
three fields were measured for each cell line under the same con-
ditions. The results are expressed as the mean (%) 
 
6
 
 SD. 
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et al., 1999). Therefore, we examined the role of ATF-2
in BMP-induced cardiomyocyte differentiation. First, we
performed Northern blot analysis to examine the expres-
sion level of ATF-2 mRNA during cardiomyocyte differ-
entiation of P19CL6. Expression of ATF-2 mRNA was de-
tected even before the treatment with DMSO (on day 0),
but became more abundant after DMSO treatment (Fig. 3
A). We further examined whether the ATF-2 protein was
activated during differentiation of P19CL6. Western blot
analysis using anti–phospho-ATF-2 antibody, which rec-
ognizes only activated ATF-2, revealed that ATF-2 was
slightly activated even before the differentiation and its
activity was enhanced on day 6 (Fig. 3 B). These results
suggest that not only expression of ATF-2 mRNA but also
the activity of the ATF-2 protein are upregulated during
differentiation induced by DMSO treatment.
 
ATF-2 Was Involved in Transactivation of 
the 
 
b
 
MHC Promoter with Synergistic 
Enhancement by Smads and TAK1
 
To examine the role of ATF-2 in the regulation of cardiac-
specific gene promoters, cotransfection experiments were
performed using reporter plasmids containing luciferase
gene driven by the 
 
b
 
MHC promoter in the presence or the
absence of BMP stimulation. Expression vectors encod-
ing Smad1/4, the constitutively active form of TAK1
(caTAK1), and ATF-2 were used as effectors. P19CL6
cells cultured with 1% DMSO were transfected with effec-
tor and reporter plasmids on day 5 by the calcium phos-
phate method. The cell lysates were extracted on day 7 (48 h
after transfection) and the luciferase activities were ana-
lyzed. The BMP treatment was performed at a final con-
centration of 100 ng/ml for 24 h before the lysate prepara-
tion. The 
 
b
 
MHC promoter was slightly activated by BMP
treatment (1.8-fold; Fig. 4 A, column 1). Smad1/4 and
caTAK1 mildly stimulated this promoter activity, and
cooverexpression of Smad1/4 and caTAK1 synergistically
enhanced the activity by 3.9-fold in the presence of BMP
treatment (Fig. 4 A, columns 2–4). ATF-2 stimulated this
promoter activity by 2.1-fold in the absence of BMP treat-
ment and by 2.5-fold in the presence of BMP treatment
(Fig. 4 A, column 5). The degree of activation of this pro-
moter by ATF-2 was slightly enhanced by cooverexpres-
sion of Smad1/4 or caTAK1 (Fig. 4 A, columns 6 and 7).
Furthermore, this promoter activity was strongly en-
hanced by cooverexpression of all three effectors together,
resulting in a 3.1- and 6.4-fold stimulation in the absence
and presence of BMP treatment, respectively (Fig. 4 A,
column 8). These results suggest that cooverexpression of
ATF-2, Smad1/4, and caTAK1 synergistically activates the
 
b
 
MHC promoter during the course of differentiation in
P19CL6 cells.
To confirm that ATF-2, Smads, and TAK1 coopera-
tively activate the 
 
b
 
MHC promoter, we next examined
whether Smad6 (an inhibitory Smad) or the dominant neg-
ative form of TAK1 (dnTAK1) inhibits transactivation of
this promoter by ATF-2. Overexpression of Smad6 or
dnTAK1 partially inhibited the ATF-2–induced promoter
activation both in the presence or in the absence of BMP
treatment (Fig. 4 B). These results suggest that the block-
ade either of the Smad or the TAK1 pathway can inhibit
the stimulatory effect of ATF-2 on the 
 
b
 
MHC promoter
and that ATF-2 induces the transactivation of this pro-
moter through BMP signaling.
 
Overexpression of the Dominant Negative 
Form of ATF-2 Inhibited Cardiomyocyte 
Differentiation of P19CL6
 
To further clarify the role of ATF-2 in cardiomyocyte dif-
ferentiation, we transfected expression plasmids contain-
ing two ATF-2 mutants, ATF-2Ala and ATF-2
 
D
 
107, into
parental P19CL6 cells. ATF-2Ala is the mutant in which
the three SAPK phosphorylation sites (Thr-69, Thr-71,
and Ser-90) are replaced by alanine, and ATF-2
 
D
 
107 is the
truncated mutant which lacks the NH
 
2
 
-terminal 107 amino
acids including all three SAPK phosphorylation sites
(Sano et al., 1999). These two mutants cannot be phos-
phorylated by TGF-
 
b
 
 signaling via TAK1 and p38 and are
expected to act as dominant negative forms. The cells cul-
tured with 1% DMSO were transfected on day 3 by the li-
Figure 2. Inhibition of cardiomyocyte dif-
ferentiation by overexpression of Smad6.
(A) In the absence of DMSO,
P19CL6Smad6 cells grew well and did not
differentiate into any specific cells like pa-
rental P19CL6 cells (a and b). When 1%
DMSO was added to the media,
P19CL6Smad6 cells did not differentiate
into MF20-positive beating cardiomyocytes
in contrast to parental P19CL6 cells (c).
The cells were stained with MF20 (a and c)
or Hoechst dye (b). Bar, 50 mm. (B) Ex-
pression of cardiac-specific genes was de-
tected in P19CL6 cells but not in
P19CL6Smad6 cells. RNA was prepared
from parental P19CL6 cells and
P19CL6Smad6 cells on day 0 (before
DMSO treatment) (lanes 1 and 4), day 6
(lanes 2 and 5), and day 12 (lanes 3 and 6). RT-PCR was performed to analyze Csx/Nkx-2.5 mRNA. 10 mg of RNA from each sample
was subjected to Northern blot analysis for other genes. Ethidium bromide staining of rRNA is presented at the bottom to show that the
same amount of intact RNA was loaded in each lane. 
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pofection method, and then the differentiation ability was
assessed at day 14. P19CL6 cells transfected with either of
the two ATF-2 mutants less efficiently differentiated into
MF20-positive beating cardiomyocytes than the control
P19CL6 cells (Fig. 5 A). The percentage of positive areas
stained by MF20 was estimated to be 
 
z
 
50% lower in the
cells transfected with the mutants than in the control
P19CL6 cells (Fig. 5 B).
To clarify the correlation between expression of the
ATF-2 mutants and the phenotype of the P19CL6 differ-
entiation at the cellular level, we examined whether car-
diomyocyte differentiation was inhibited in the cells over-
expressing the ATF-2 mutants. P19CL6noggin cells were
transfected simultaneously with expression vectors encod-
ing ATF-2
 
D
 
107 and those containing GFP on day 3, and
then were stained by MF20 on day 12. The MF20-positive
signals were detected in GFP-negative cells (Fig. 5 C, ar-
rows) but not in GFP-positive cells (Fig. 5 C, arrowheads),
suggesting that the myocyte differentiation was inhibited
in the cells overexpressing the dominant negative form of
ATF-2 but not in the cells which were not transfected with
the ATF-2 mutant.
Northern blot analysis revealed that the expression level
of cardiac genes such as GATA-4, MEF2C, and MLC2v
was reduced in the cells transfected with ATF-2
 
D
 
107 (Fig.
5 D). To confirm the inhibitory effects of these dominant
negative mutants on cardiomyocyte differentiation, we
further examined the promoter activities of cardiac genes.
P19CL6 cells were cultured with 1% DMSO and trans-
fected on day 5 by the calcium phosphate method with ef-
fector plasmids carrying ATF-2
 
D
 
107 and reporter plas-
mids containing promoters of several cardiac genes such as
 
b
 
MHC, ANP, BNP, and skeletal 
 
a
 
-actin. The cell lysates
were extracted on day 7 and the luciferase activities were
analyzed. The ATF-2 mutant significantly inhibited the
 
b
 
MHC, ANP, and BNP promoter activities whereas the
promoter activity of skeletal 
 
a
 
-actin was not affected (Fig.
5 E). All these results suggest that overexpression of the
dominant negative form of ATF-2 inhibits expression of at
least some set of cardiac-specific genes and terminal car-
diomyocyte differentiation in this P19CL6 system.
 
Overexpression of ATF-2 Enhanced the BMP-induced 
Cardiomyocyte Differentiation of P19CL6noggin
 
To examine whether ATF-2 promotes cardiomyocyte dif-
ferentiation of P19CL6, we transfected expression plas-
mids encoding wild-type ATF-2 along with those carrying
Smads and TAK1 mutants into P19CL6noggin cells. The
cells were transfected with the expression vectors on day 3
by the lipofection method and then were immunostained
by MF20 to evaluate the differentiation efficiency. Overex-
pression of dnTAK1 partially inhibited Smad1/4-induced
cardiomyocyte differentiation of P19CL6noggin whereas
Smad6 blocked caTAK1-induced differentiation (Fig. 6,
columns 2–5), suggesting that Smads and TAK1 act in par-
allel, at least partially, against their downstream targets.
Cooverexpression of Smad1/4 and caTAK1 enhanced the
differentiation efficiency (Fig. 6, column 6). Overexpres-
sion of wild-type ATF-2 alone restored the ability of
P19CL6noggin to differentiate into cardiomyocytes (Fig. 6,
column 7), and the differentiation efficiency was enhanced
by simultaneous overexpression along with Smad1/4 or
caTAK1 (Fig. 6, columns 8 and 9). Furthermore, differenti-
ation of P19CL6noggin into cardiomyocytes was most
strongly induced by overexpression of all inducers together
(Fig. 6, column 10). These results suggest that ATF-2,
Smad1/4, and caTAK1 cooperatively induce differentia-
tion of P19CL6noggin into cardiomyocytes.
 
Discussion
 
In this study, we obtained the following results: (a) The
Smad pathway is necessary for BMP-induced cardiomyo-
cyte differentiation in P19CL6; (b) ATF-2, a common nu-
clear target of the Smad and the TAK1 pathways, is
involved in transcriptional activation of some cardiac-spe-
cific genes and terminal cardiomyocyte differentiation in
Figure 3. The expression levels and the activity of ATF-2 were
increased during differentiation of P19CL6 cells. (A) RNA was
prepared from parental P19CL6 cells on day 0 (lane 1), day 6
(lane 2), and day 12 (lane 3). 10 mg of RNA from each sample
was subjected to Northern blot analysis for ATF-2 mRNA.
Ethidium bromide staining of rRNA is presented at the bottom
to show that the same amount of intact RNA was loaded in each
lane. (B) Whole cell extracts from P19CL6 cells on day 0 (lane 1)
and day 6 (lane 2) of differentiation were prepared and analyzed
by SDS-PAGE followed by Western blotting. The phosphoryla-
tion of ATF-2 was examined using anti-phospho-ATF-2 antibody
which detects phosphorylation of Thr-71 specifically.
Figure 4. ATF-2 stimulated the promoter activity of bMHC
gene by the synergistic manner with Smad1/4 and TAK1. P19CL6
cells were cultured in the presence of 1% DMSO and were trans-
fected on day 5 by the calcium phosphate method with reporter
plasmids containing luciferase gene driven by bMHC promoter
and expression plasmids carrying ATF-2, Smad1, Smad4, and
caTAK1 (A) and ATF-2, Smad6, and dnTAK1 (B) as effector
plasmids. The cell lysates were extracted on day 7 and the lu-
ciferase activities were analyzed. The degree of activation is indi-
cated as means 6 SD. Dotted columns, BMP treatment (2).
Closed columns, BMP treatment (1). 
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P19CL6; and (c) Smads, TAK1, and ATF-2 cooperatively
induce differentiation of P19CL6 cells into cardiomyocytes.
 
Smads Are Required for BMP-induced 
Cardiomyocyte Differentiation
 
We previously reported that BMPs induce cardiomyocyte
differentiation through TAK1 (Monzen et al., 1999). In
the study, we established a permanent P19CL6 cell line,
P19CL6noggin, which constitutively overexpresses the
BMP antagonist noggin. The secreted protein noggin was
first identified as a dorsalizing factor localized in the Spe-
mann organizer in 
 
Xenopus
 
 embryos (Smith and Harland,
1992). Subsequent studies have demonstrated that noggin
binds specifically to BMP-2 and BMP-4 with high affinity
and also to BMP-7 with lower affinity, thereby abolishing
the activity of BMPs by blocking the binding of BMPs
to cognate cell surface receptors (Zimmerman et al.,
1996). Although almost all parental P19CL6 cells differen-
tiated into beating cardiomyocytes when treated with 1%
DMSO, P19CL6noggin cells did not differentiate into
beating cardiomyocytes nor express cardiac transcription
factors or contractile protein genes. The failure of differ-
entiation was rescued by overexpression of BMP-2 using
adenovirus-mediated gene delivery or addition of BMP
protein to the culture media, indicating that BMPs are in-
dispensable for cardiomyocyte differentiation in this sys-
tem. Furthermore, overexpression of TAK1 restored the
ability of P19CL6noggin cells to differentiate into car-
diomyocytes and concomitantly express some cardiac genes,
whereas overexpression of the dominant negative form of
TAK1 in parental P19CL6 cells inhibited cardiomyocyte
differentiation. These results suggest that TAK1 plays a
pivotal role in the cardiogenic BMP signaling pathway
(Monzen et al.
 
,
 
 1999).
In this study, coexpression of Smad1 and Smad4 also re-
stored the ability of P19CL6noggin cells to differentiate
into cardiomyocytes with concomitant expression of car-
diac transcription factors such as Csx/Nkx-2.5, GATA-4,
and MEF2C, and contractile protein genes such as MHC
and MLC2v. These results suggest that Smads also mediate
BMP-induced transactivation of cardiac-specific genes and
induction of terminal differentiation of P19CL6 cells into
cardiomyocytes. Expression of endogenous Smad1 and
Smad4 was not detected in the differentiating P19CL6 cells
Figure 5. The dominant negative forms of ATF-2 inhibited ex-
pression of cardiac-specific genes and terminal cardiomyocyte
differentiation. (A) P19CL6 cells were cultured with 1% DMSO
and transfected with either of two ATF-2 mutants, ATF-2Ala (b)
and ATF-2D107 (c), on day 3 by the lipofection method. The cells
were then immunostained with MF20 on day 14. Bar, 250 mm.
(B) Quantification of the areas stained by MF20 in P19CL6 cells.
The percentage of areas positive for MF20 in the P19CL6 cells
transfected with the ATF-2 mutants (lanes 2 and 3) was z50%
lower than the control P19CL6 cells (lane 1). The areas of at least
three fields were measured for each cell line under the same con-
ditions. The results are expressed as means (%) 6 SD. (C) The
correlation between overexpression of the ATF-2 mutant and the
P19CL6 differentiation. P19CL6 cells were transfected with ex-
pression plasmids encoding ATF-2D107 along with GFP expres-
sion plasmids on day 3 and then immunostained by MF20 on day
12. (a) Hoechst dye; (b) GFP; (c) MF20. Arrows, a GFP-negative cell; arrowheads, a GFP-positive cell. Bar, 20 mm. (D) Expression of
cardiac-specific genes in the control P19CL6 cells (lane 1) and P19CL6 cells transfected with ATF-2D107 (lane 2). RNA was prepared
on day 14 and 10 mg of RNA from each sample was subjected to Northern blot analysis. Ethidium bromide staining of rRNA is pre-
sented at the bottom to show that the same amount of intact RNA was loaded in each lane. (E) P19CL6 cells were cultured with 1%
DMSO and transfected on day 5 by the calcium phosphate method with effector plasmids carrying ATF-2D107 and reporter plasmids
containing promoters of several cardiac genes such as bMHC, ANP, BNP, and skeletal a-actin. The cell lysates were extracted on day 7
and the luciferase activities were analyzed. The degree of activation is indicated as means 6 SD.Monzen et al. Roles for Smads, TAK1, and ATF-2 in Cardiomyogenesis 695
by Northern blot analysis (data not shown), implying that
expression levels of these Smads were relatively low in this
cell line. The correlation between overexpression of Smads
and the P19CL6 differentiation at the cellular level was
confirmed by the cotransfection experiments using Smad1/4
and GFP expression plasmids followed by immunostaining
with MF20, which demonstrated that only GFP-positive
cells (i.e., Smads-overexpressing cells) were stained posi-
tively by MF20. The reasons why overexpression of Smad1
alone could not restore the differentiation ability remains
unknown. One possibility is that only overexpression of
one component of heterooligomers are not sufficient for
effective heterooligomer formation and subsequent nu-
clear translocation in the absence of ligand stimulation. In
fact, immunofluorescence experiments revealed that the
majority of exogenous Smad1 was localized in the cyto-
plasm in P19CL6noggin cells, suggesting that only a small
part of the Smad proteins can translocate into the nucleus
in the absence of BMP function. Excessive amounts of both
ligand-specific and common-partner Smads may be neces-
sary for effective hetero-oligomer formation.
Overexpression of Smad6, an inhibitory Smad which has
been reported to block the TGF-b superfamily signal
transduction, inhibited expression of some set of cardiac-
specific genes and terminal differentiation of P19CL6 cells
into cardiomyoctes. These results suggest that the Smad
pathway is indispensable for normal cardiomyocyte differ-
entiation. To date, several studies have shown the impor-
tance of the Smad pathway in normal cardiac development
in vivo. Gene targeting experiments in mice have revealed
that Smad5 knockout mice exhibit morphological defects
in the developing amnion, gut, and heart which are similar
to those of BMP-2 knockout mice (Chang et al., 1999).
Smad6-deficient mice also have multiple cardiovascular
abnormalities such as hyperplasia of the cardiac valves and
outflow tract septation defects, indicating a function for
Smad6 in the regulation of endocardial cushion transfor-
mation (Galvin et al., 2000). The latter study suggests that
excess activation of the Smad pathway also causes abnor-
mal heart development. It has been reported recently that
expression of Smad6 itself is regulated by BMP-activated
Smad1/5 (Ishida et al., 2000). These observations and our
results imply that temporal and spacial precise regulation
of the Smad activities may be important for normal car-
diac development from initial cardiomyocyte differentia-
tion to terminal cardiac morphogenesis.
ATF-2 Induces Transcriptional Activation of Cardiac 
Genes through the Smad and the TAK1 Pathways 
during Cardiomyocyte Differentiation
In the previous paper (Monzen et al., 1999) and this paper,
we have provided several lines of evidence suggesting that
both the Smad and the TAK1 pathways play a crucial role
in cardiomyocyte differentiation. We next focused on the
molecular mechanisms of how both pathways coopera-
tively regulate expression of cardiac genes and induce ter-
minal cardiomyocyte differentiation. In Xenopus embryos,
overexpression of kinase-negative TAK1 has been re-
ported to inhibit the Smad1-induced ventralization (Shi-
buya et al., 1998), suggesting that the regulation by BMPs
requires cooperative actions of Smads and TAK1. It is also
noteworthy that MEKK-1, a component of the SAPK
pathway, can selectively activate Smad2-mediated tran-
scriptional activation in endothelial cells (Brown et al.,
1999). TAK1, which also stimulates the SAPK/JNK path-
way similar to MEKK-1, may activate the Smad pathway
similarly. However, little had been known about the mole-
cules that connect the Smad and the TAK1 pathways, until
the transcription factor ATF-2 was proposed to be a com-
mon nuclear target of both pathways. ATF-2 has been
demonstrated to bind directly to heterooligomers of
Smads and be phosphorylated by TGF-b signaling via
TAK1 and p38 (Hanafusa et al., 1999; Sano et al., 1999).
Both pathways have been shown to synergistically stimu-
late ATF-2 transactivating capacity (Sano et al., 1999).
From this viewpoint, we examined the involvement of
ATF-2 in BMP-induced cardiomyocyte differentiation.
ATF-2 has been shown to be ubiquitously expressed
in various human embryonic tissues and cell lines, with
the highest expression level being observed in brain
(Maekawa et al., 1989; Takeda et al., 1991). Northern blot
analysis revealed that ATF-2 mRNA was abundantly ex-
pressed during the course of differentiation in P19CL6
cells and that the expression level was higher on day 6 and
day 12 than on day 0 (i.e., before the initiation of DMSO
treatment). Furthermore, Western blot analysis demon-
strated that the phosphorylation of the ATF-2 protein was
detected during differentiation of P19CL6. These results
suggest that ATF-2 is one of the DMSO-inducible factors
(see below) and that it may play an important role in the
induction of differentiation of P19CL6.
The results of cotransfection experiments followed by
reporter gene assays demonstrated that overexpression of
ATF-2 alone stimulated the promoter activity of bMHC
gene and that cooverexpression of ATF-2, Smad1/4, and
Figure 6. Overexpression of ATF-2, Smad1/4, and caTAK1 co-
operatively rescued the ability of P19CL6noggin to differentiate
into cardiomyocytes. P19CL6 cells were cultured in the presence
of 1% DMSO and were transfected on day 3 by the lipofection
method with expression plasmids carrying ATF-2, Smads, and the
TAK1 mutants. The cells were then immunostained with MF20
on day 14. The percentage of areas positive for MF20 in the
P19CL6 cells transfected with respective plasmids was measured
at least three fields under the same conditions. The results are ex-
pressed as means (%) 6 SD.The Journal of Cell Biology, Volume 153, 2001 696
caTAK1 synergistically activated this promoter. Further-
more, overexpression of Smad6, an inhibitory Smad, and
the dominant negative form of TAK1 partially inhibited
transactivation of bMHC gene by ATF-2, suggesting that
ATF-2-induced transactivation of bMHC gene depends
on both the Smad and the TAK1 pathways. These results
are consistent with the previous reports showing synergis-
tic enhancement of ATF-2 activity by Smads and TAK1
using the CRE-containing promoters (Sano et al., 1999),
although the bMHC promoter we used does not contain
the CRE site (Strehler et al., 1985). It is possible that ATF-2
may indirectly stimulate this promoter via transactivation
of some other genes such as cardiac-specific transcription
factors. Further studies are necessary to elucidate the mo-
lecular cascade from ATF-2 to related genes needed for
the full differentiation of cardiac precursor cells into car-
diomyocytes.
ATF-2 Plays a Pivotal Role in Cardiomyocyte 
Differentiation of P19CL6
To test the importance of ATF-2 for the actual differentia-
tion of P19CL6, we transfected ATF-2 mutants into
P19CL6 and examined the differentiation efficiency, ex-
pression of cardiac-specific genes, and activation of pro-
moters. Our results demonstrated that overexpression of
the dominant negative form of ATF-2 (dnATF-2) partially
inhibited (a) promoter activities of some cardiac genes
such as bMHC, ANP, and BNP, (b) mRNA expression of
GATA-4, MEF2C, and MLC2v, and (c) terminal car-
diomyocyte differentiation of P19CL6 cells, indicating that
ATF-2 plays a crucial role in differentiation into car-
diomyocytes. The reduction of promoter activities and the
differentiation efficiency by overexpression of dnATF-2
was estimated to be z50%. This result was thought to be
compatible with the transfection efficiency by the lipofec-
tion method, which was estimated to range from z40 to
60% by counting GFP-positive cells 1 d after the transfec-
tion of GFP expression plasmids (data not shown). All
these results strongly suggest that ATF-2 plays a pivotal
role in transactivation of some cardiac-specific genes and
terminal cardiomyocyte differentiation.
We further established the permanent P19CL6 cell line
which constitutively overexpresses one of the dnATF-2
mutants, ATF-2D107 (P19CL6ATF-2D107). Unexpect-
edly, a part of P19CL6ATF-2D107 cells differentiated into
beating cardiomyocytes by the treatment with DMSO, al-
though the differentiation efficiency was reduced com-
pared with parental P19CL6 (data not shown). This is
probably because endogenous ATF-2 was so abundantly
expressed in P19CL6 cells that stable expression of
dnATF-2 could not completely block its activity. In fact,
Northern blot analysis revealed that the expression level
of dnATF-2 was almost the same as that of endogenous
ATF-2 on day 6 in P19CL6ATF-2D107 cells (data not
shown). On the other hand, transient transfection provides
much higher expression of exogenous genes, so that it is
probable that dnATF-2 could completely inhibit the ef-
fects of endogenous ATF-2 in the P19CL6 cells when tran-
siently transfected. The transient transfection experiments
clearly suggest that ATF-2 plays a critical role in cardio-
myocyte differentiation.
In the in vivo situation, ATF-2 knockout mice generated
by gene targeting exhibit lowered postnatal viability and
growth, in addition to a defect in endochondrial ossifica-
tion and a reduced number of cerebellar Purkinje cells
(Reimold et al., 1996). Another group subsequently re-
ported that mouse ATF-2 null mutants display features of
a severe type of meconium aspiration syndrome (Maekawa
et al., 1999). Neither embryonic lethality nor abnormal car-
diac phenotype has been reported in these knockout mice,
which is inconsistent with our in vitro results. This is possi-
bly because genetic redundancies among the ATF/CREB
family members, all of which bind to the CRE site, may
rescue the phenotypes of these knockout mice. The under-
standing of the precise molecular requirement of the ATF/
CREB family members for differentiation of cardiac pre-
cursor cells in vivo awaits further investigation.
Cotransfection experiments into P19CL6noggin cells us-
ing wild-type ATF-2 along with Smad1/4 and caTAK1 re-
vealed that overexpression of wild-type ATF-2 alone re-
stored the ability of P19CL6noggin to differentiate into
cardiomyocytes, although the efficiency was relatively low
probably because of the lack of BMP stimulation, and that
the differentiation efficiency was most strongly enhanced
when Smad1/4 and caTAK1 were also overexpressed.
These results indicate that cooverexpression of ATF-2,
Smad1/4, and caTAK1 cooperatively promotes the ability
of P19CL6noggin to differentiate into cardiomyocytes
and suggest that ATF-2 is involved in differentiation of
P19CL6 into cardiomyocytes downstream of the Smad and
the TAK1 pathways.
Both the binding of Smads with ATF-2 and phosphory-
lation of ATF-2 by TAK1 and p38 are thought to contrib-
ute to the enhancement of the DNA binding affinity of
ATF-2 and subsequent transactivational responses. The
heterooligomer of Smad3/4 has been reported to bind di-
rectly to ATF-2 through the MH1 region of Smad3/4 and
the b-ZIP region of ATF-2 and enhance the transactivating
capacity of ATF-2 (Sano et al., 1999). In this sense, Smads
resemble adenovirus E1A, which stimulates CRE-depen-
dent transcription via binding to the b-ZIP region of
ATF-2 (Liu and Green, 1994). Expression of E1A has
been shown to induce differentiation of several other cell
lines such as F9 cells (Montano and Lane, 1987; Velcich
and Ziff, 1989). We have preliminary data demonstrating
that overexpression of E1A strongly restored the ability of
P19CL6noggin cells to differentiate into cardiomyocytes,
suggesting that E1A, instead of Smads, can induce car-
diomyocyte differentiation through the activation of ATF-2
(Monzen and Komuro, unpublished data). Meanwhile, it
has been reported that CREB-binding protein (CBP),
which was originally identified as a coactivator of CREB,
directly binds to the b-ZIP region of ATF-2 and potenti-
ates transactivation of ATF-2 (Sano et al., 1998). However,
E1A also has been demonstrated to suppress the CREB-
mediated transcription by competing with p300/CBP-asso-
ciated factor (P/CAF) for binding to p300/CBP (Yang et
al., 1996). Moreover, it has been reported recently that
ATF-2 has intrinsic histone acetyltransferase (HAT) activ-
ity as well as p300/CBP and P/CAF and that phosphoryla-
tion of ATF-2 controls its intrinsic HAT activity and its ac-
tion on CRE-dependent transcription (Kawasaki et al.,
2000). Further studies are necessary to dissect the molecu-Monzen et al. Roles for Smads, TAK1, and ATF-2 in Cardiomyogenesis 697
lar mechanisms of how these transcriptional cofactors
work during differentiation into cardiomyocytes.
General Consideration
A speculative diagram of the regulatory cascade control-
ling differentiation of P19CL6 cells into cardiomyocytes is
shown in Fig. 7 as a summary of our study. BMPs induce
expression of some cardiac-specific genes and terminal
cardiomyocyte differentiation through the Smad and the
TAK1 pathways. Both pathways cooperatively activate
the transcription factor ATF-2, resulting in the transacti-
vation of some set of genes related to terminal cardiomyo-
cyte differentiation. As we showed in the previous report
(Monzen et al., 1999), some other DMSO-inducible fac-
tors independent of BMP signaling are necessary for the
terminal differentiation (indicated as “X” and “Y” on Fig.
7), because only activation of BMP signaling is not suffi-
cient to induce differentiation in the absence of DMSO.
Thus, BMP signal transduction pathways and its down-
stream transcription factors are the central molecules of
this regulatory network controlling cardiac differentiation
as well as unknown DMSO-inducible factors. The identifi-
cation of cardiac genes regulated by ATF-2 and signals in-
duced by DMSO in this system will provide new insights
into the understanding of the precise molecular mecha-
nisms by which cardiomyocyte differentiation is regulated.
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